;Potent, Orally Bioavailable and Efficacious Macrocyclic Inhibitors of Factor XIa. Discovery of Pyridine-Based Macrocycles Possessing Phenylazole Carboxamide P1 Groups.
;
J.Med.Chem. (2019)
Orally bioavailable amine-linked macrocyclic inhibitors of factor XIa.
Bioorg.Med.Chem.Lett. (2020)
;Structure based design of macrocyclic factor XIa inhibitors: Discovery of cyclic P1 linker moieties with improved oral bioavailability.
;
Bioorg.Med.Chem.Lett. (2019)
Macrocyclic factor XIa inhibitors.
Bioorg. Med. Chem. Lett. (2017)
Discovery of a Parenteral Small Molecule Coagulation Factor XIa Inhibitor Clinical Candidate (BMS-962212).
J. Med. Chem. (2017)
Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
J. Med. Chem. (2017)
Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.
Bioorg. Med. Chem. Lett. (2017)
Novel phenylalanine derived diamides as Factor XIa inhibitors.
Bioorg. Med. Chem. Lett. (2016)
Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.
Bioorg. Med. Chem. (2016)
Pyridine and pyridinone-based factor XIa inhibitors.
Bioorg. Med. Chem. Lett. (2015)
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.
Bioorg. Med. Chem. Lett. (2015)
;Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.
;
ACS Med Chem Lett (2015)
Tetrahydroquinoline derivatives as potent and selective factor XIa inhibitors.
J. Med. Chem. (2014)
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.
J. Med. Chem. (2014)